Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 14
- Basım Tarihi: 2018
- Doi Numarası: 10.4103/0973-1482.235355
- Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Anahtar Kelimeler: Arylesterase, breast cancer, cancer risk, cut-off value, neoadjuvant, paraoxonase, screening, BODY-MASS INDEX, COLORECTAL-CANCER, OXIDATIVE STRESS, CARCINOGENESIS, INFLAMMATION, POLYMORPHISM, RADICALS, PON1, RISK
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet
Özet
Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.